Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Pulmonary Ventilation Function Between Patients With Primary and Recurrent Incisional Hernia: a Cross-sectional Study
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 164
- Registration Number
- NCT05991024
- Locations
- 🇨🇳
Yiming Lin, Shanghai, China
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 43
- Registration Number
- NCT05982834
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 87
- Registration Number
- NCT05982301
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 114
- Registration Number
- NCT05975749
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT05976932
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 3200
- Registration Number
- NCT05976152
- Locations
- 🇨🇳
Donggang Center Hospitol, Dandong, Liaoning, China
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 101
- Registration Number
- NCT05970705
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
PET-CT Predicting Segement Specific Lymph Nodes Metastasis
Recruiting
- Conditions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 280
- Registration Number
- NCT05970913
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, China
Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT05969899
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Fudan University, Shanghai, Pudong, China
Phase II Study of Sufantinib Combined With AG Versus AG First-line in the Treatment of LAPC or mPC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT05969171
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath